Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV + male participants on antiretroviral therapy (undetectable viral loads, CD4 + T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
【저자키워드】 COVID-19, Adaptive immunity, AIDS/HIV, Cellular immune response, T cells, 【초록키워드】 SARS-CoV-2, HIV, immune response, vaccination, Trial, Immunity, serology, neutralization, SARS-COV-2 infection, variants of concern, CD4, ACE-2, Duration, Cohort, T cell, AZD1222, response, Antiretroviral therapy, IgG ELISA, T cell response, ChAdOx1 nCoV-19, Cell-mediated immunity, SARS-CoV-2 spike, marker, Evidence, dose, humoral, cross-reactive, regimen, Support, Beta coronaviruses, no significant difference, individual, viral loads, HIV-uninfected, Meso Scale Discovery, vaccinate, IFN-γ ELISPOT, T cell proliferation, prevaccination, greater, detectable, majority, correlated, with HIV, baseline, male participant, undetectable, 【제목키워드】 vaccination, ChAdOx1 nCoV-19, with HIV,